​

Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TVTX Stock Forecast

Travere Therapeutics (TVTX) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $42.00, with a high of $49.00 and a low of $35.00. This represents a 43.34% increase from the last price of $29.30.

$5 $14 $23 $32 $41 $50 High: $49 Avg: $42 Low: $35 Last Closed Price: $29.3

TVTX Stock Rating

Travere Therapeutics stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (83.33%), 3 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 3 15 Strong Sell Sell Hold Buy Strong Buy

TVTX Price Target Upside V Benchmarks

TypeNameUpside
StockTravere Therapeutics43.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$49.00$42.00
Last Closing Price$29.30$29.30$29.30
Upside/Downside-67.24%43.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 261122--15
Jan, 261122--15
Dec, 251122--15
Nov, 252112--15
Oct, 252112--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 14, 2026Vamil DivanGuggenheim$49.00$28.3972.60%67.24%
Sep 10, 2025Maury RaycroftJefferies$35.00$27.3128.16%19.45%
Oct 31, 2024Liisa BaykoEvercore ISI$33.00$17.5088.57%12.63%
Oct 21, 2024Mohit BansalWells Fargo$27.00$17.8751.09%-7.85%
Oct 10, 2024Liisa BaykoEvercore ISI$30.00$18.0766.02%2.39%
Oct 09, 2024Jason ZemanskyBank of America Securities$20.00$15.2131.49%-31.74%
Oct 01, 2024Carter GouldBarclays$18.00$13.9928.66%-38.57%
Sep 27, 2024Vamil DivanGuggenheim$23.00$15.0452.93%-21.50%
Sep 27, 2024Ed ArceH.C. Wainwright$18.00$15.0419.68%-38.57%
Sep 27, 2024Greg HarrisonBank of America Securities$18.00$14.0128.48%-38.57%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 06, 2026Piper SandlerNeutralNeutralhold
Jan 14, 2026GuggenheimBuyBuyhold
Nov 04, 2025Piper SandlerNeutralNeutralhold
Oct 31, 2025CitigroupBuyBuyhold
Oct 31, 2025Cowen & Co.BuyBuyhold
Sep 11, 2025Wells FargoOverweightOverweighthold
Aug 28, 2025H.C. WainwrightBuyBuyhold
Aug 10, 2025CitigroupBuyBuyhold
Aug 07, 2025ScotiabankOutperformOutperformhold
May 16, 2025CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.01$-4.37$-1.50$-4.08$-0.29---
Avg Forecast$-3.01$-4.48$-1.62$-3.66$-1.13$0.60$1.11$1.88
High Forecast$-2.24$-3.17$-1.39$-3.54$-0.39$2.59$3.24$2.67
Low Forecast$-4.59$-6.86$-1.79$-3.82$-1.75$-0.64$0.40$0.70
Surprise %--2.46%-7.41%11.48%-74.34%---

Revenue Forecast

$100M $290M $480M $670M $860M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$131.84M$109.46M$145.24M$233.18M$490.73M---
Avg Forecast$225.72M$208.36M$195.51M$230.58M$342.48M$478.46M$630.10M$780.85M
High Forecast$316.57M$293.80M$198.06M$243.97M$415.94M$488.58M$833.66M$1.03B
Low Forecast$181.47M$161.65M$193.14M$220.79M$266.55M$468.34M$325.75M$403.68M
Surprise %-41.59%-47.47%-25.71%1.13%43.29%---

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-180.09M$-278.48M$-111.40M$-321.55M$-25.55M---
Avg Forecast$-142.95M$-176.32M$-376.33M$-273.28M$-113.69M$41.94M$117.12M$139.77M
High Forecast$-114.36M$-141.05M$-301.07M$-262.54M$-29.06M$191.99M$240.53M$198.47M
Low Forecast$-171.54M$-211.58M$-451.60M$-284.02M$-129.88M$-47.47M$29.42M$52.01M
Surprise %25.98%57.94%-70.40%17.66%-77.53%---

TVTX Forecast FAQ

Is Travere Therapeutics stock a buy?

Travere Therapeutics stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Travere Therapeutics is a favorable investment for most analysts.

What is Travere Therapeutics's price target?

Travere Therapeutics's price target, set by 18 Wall Street analysts, averages $42 over the next 12 months. The price target range spans from $35 at the low end to $49 at the high end, suggesting a potential 43.34% change from the previous closing price of $29.3.

How does Travere Therapeutics stock forecast compare to its benchmarks?

Travere Therapeutics's stock forecast shows a 43.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Travere Therapeutics over the past three months?

  • February 2026: 6.67% Strong Buy, 80.00% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 6.67% Strong Buy, 80.00% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 6.67% Strong Buy, 80.00% Buy, 13.33% Hold, 0% Sell, 0% Strong Sell.

What is Travere Therapeutics’s EPS forecast?

Travere Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $0.6, marking a -306.90% decrease from the reported $-0.29 in 2025. Estimates for the following years are $1.11 in 2027, and $1.88 in 2028.

What is Travere Therapeutics’s revenue forecast?

Travere Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $478.46M, reflecting a -2.50% decrease from the reported $490.73M in 2025. The forecast for 2027 is $630.1M, and $780.85M for 2028.

What is Travere Therapeutics’s net income forecast?

Travere Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $41.94M, representing a -264.16% decrease from the reported $-25.546M in 2025. Projections indicate $117.12M in 2027, and $139.77M in 2028.